Annual report pursuant to Section 13 and 15(d)

Revenue (Tables)

v2.4.1.9
Revenue (Tables)
12 Months Ended
Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Revenue from Product Sales

The Company has not generated revenue from product sales. The Company has generated revenue pursuant to (i) license and collaboration agreements, which include upfront payments for licenses or options to obtain licenses, payments for research and development services and milestone payments, and (ii) government grants, which are shown in the table below for periods specified:

 

     Years ended December 31,  
     2014      2013  

License fees

   $ 473,039       $ 5,159,425   

Research and development services

     876,619         3,591,855   

Milestone payments

     3,184,988         1,128,630   

Government grants

     830,408         2,547,382   
  

 

 

    

 

 

 

Total Revenue

$ 5,365,054    $ 12,427,292   
  

 

 

    

 

 

 
Revenue Received

The Company has received the following amounts:

 

     Years ended December 31,  
     2014      2013  

Amounts received

   $ —         $ 2,915,559   

Revenue from grant

   $ 714,388       $ 2,430,358   
Balance Sheet Items Related to FP7 Agreement

The following balance sheet items relate to the FP7 agreement:

 

     December 31,  
     2014      2013  

Other current assets (receivables from FP7 grant)

   $ 857,489       $ 261,568   

Cash (restricted cash)

   $ —         $ 72,497   

Deferred revenue

   $ —         $ 69,444